Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CLNN - Clene Inc


IEX Last Trade
5.23
-0.150   -2.868%

Share volume: 23,471
Last Updated: Fri 30 Aug 2024 09:59:36 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.38
-0.15
-2.79%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.41%
1 Month
16.85%
3 Months
-22.77%
6 Months
-39.29%
1 Year
-65.37%
2 Year
-91.19%
Key data
Stock price
$5.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$3.82 - $15.57
52 WEEK CHANGE
-$0.64
MARKET CAP 
34.097 M
YIELD 
N/A
SHARES OUTSTANDING 
6.470 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.87
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$61,311
AVERAGE 30 VOLUME 
$255,264
Company detail
CEO:
Region: US
Website: clenenanomedicine.com
Employees: 62
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.

Recent news